We have studied 704 patients with CAD in order to assess whether plasma levels of calcidiol (a vitamin D metabolite) and FGF-23 are related to the incidence of adverse outcomes, and the potential influence of their relationship on the prognosis. The gene discussed is FGF23; the disease is coronary artery disorder.